FDA approves GSK's shingles vaccine with Agenus' QS-21 Stimulon® adjuvant
Agenus announced the FDA granted marketing authorization to GSK herpes zoster vaccine, SHINGRIX, containing Agenus' proprietary immune adjuvant QS-21 Stimulon®. SHINGRIX is indicated for prevention of herpes zoster (also known as shingles) in adults aged 50 years and older. October 20, 2017